In a recent Commentary in the ARCHIVES, Dr Moser1 has erroneously concluded that thiazide diuretics are the "gold standard" of hypertensive therapy and that they do not cause "metabolic abnormalities" such as dyslipidemia, hyperglycemia, new-onset diabetes, hypokalemia, or renal insufficiency. His conclusions are based on inherent design flaws and subsequent inaccurate data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), as well as a selected bias toward older studies, while ignoring recent clinical trials and even the reported diuretic-induced metabolic issues from ALLHAT. The Systolic Hypertension in the Elderly Program (SHEP) study2 found no reduction in any cardiovascular events at 1 year in the 7.2% of subjects with hypokalemia (serum potassium level <3.5 mmol/L) treated with low-dose chlorthalidone at 25 mg/d. The Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE) study3 confirms the metabolic dysfunction induced by thiazide diuretics alone or in combination with a β-blocker. The diuretic–β-blocker combination therapy compared with a calcium channel blocker–angtiotensin receptor blocker combination therapy resulted in a significantly greater incidence of insulin resistance, hyperglycemia, new-onset diabetes mellitus, dyslipidemia, metabolic syndrome, hypokalemia, hyperuricemia, and increased serum creatinine level at 1 year in a group of previously untreated hypertensive subjects.3 Other prospective clinical trials4- 7 and epidemiological studies8 have demonstrated more hyperglycemia and new-onset diabetes mellitus with use of diuretics4 and β-blockers5 compared with angiotensin-converting enzyme inhibitor,4,6 angiotensin receptor blocker,5 or calcium channel blocker4 use, as well as more renal insufficiency.7- 9 Finally, thiazide diuretics increase homocysteine levels (≥16%), which may blunt their cardiovascular protection in coronary heart disease and stroke symdrome.9
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
In one very large trial, investigators randomly allocated more than 6000 subjects to receive...
Users' Guides to the Medical Literature
Table 9.2-3 Refuted Evidence From Observational Studiesa
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.